Weekly discussions on the latest evidence in hematologic oncology - from landmark trials to practice-changing papers.

pulsosaudepodcast@gmail.com

PAPER:

• Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
• Authors: Leleu X, Hulin C, Lambert J et al.
• Journal: Nature medicine
• https://doi.org/10.1038/s41591-024-03050-2

Weekly discussions on the latest evidence in hematologic oncology - from landmark trials to practice-changing papers.

pulsosaudepodcast@gmail.com

PAPER:

• Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
• Authors: Wang M, Jurczak W, Trneny M et al.
• Journal: The Lancet. Oncology
• https://doi.org/10.1016/S1470-2045(24)00682-X

Weekly discussions on the latest evidence in hematologic oncology - from landmark trials to practice-changing papers.

pulsosaudepodcast@gmail.com

PAPER:

• Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study
• Authors: Peters C, Dalle JH, Locatelli F et al.
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• https://doi.org/10.1200/JCO.20.02529